Livingstone L R, Jones M E
Department of Biochemistry and Nutrition, School of Medicine, University of North Carolina at Chapel Hill 27514.
J Biol Chem. 1987 Nov 15;262(32):15726-33.
Orotate phosphoribosyltransferase (EC 2.4.2.10) and orotidine 5'-monophosphate decarboxylase (EC 4.1.1.23) are the final two of six enzymatic steps required in the de novo biosynthesis of uridine 5'-monophosphate (UMP). Earlier work of this laboratory showed that, in the mouse Ehrlich ascites carcinoma, both of these enzymatic activities were contained on the single multifunctional polypeptide chain, UMP synthase. We report here that the placenta provided an available human source for UMP synthase with 40-fold higher orotate phosphoribosyltransferase and orotidine 5'-monophosphate decarboxylase specific activities than erythrocytes, a human source previously used by others. By using the placenta as a source of UMP synthase and by developing a novel purification procedure different from that used in the purification of UMP synthase from the Ehrlich ascites carcinoma (the only other homogeneous preparation of a mammalian UMP synthase), we achieved the purification of human UMP synthase to apparent homogeneity. This represents the first publication to homogeneity of UMP synthase from a human source as well as from a source other than malignant cell lines. Contrary to earlier reports human placental UMP synthase was found to be a multifunctional protein containing both enzymatic activities on a single polypeptide of 51,000 molecular weight. Preliminary characterization of the human placental UMP synthase showed it to be similar to UMP synthase from the Ehrlich ascites carcinoma in subunit molecular weight, native molecular weight, isozyme pattern (although not absolute pI values), pH optima of enzymatic activities, and kinetic constants for orotidine 5'-monophosphate (Km) and 6-azauridine 5'-monophosphate (Ki) at the decarboxylase site.
乳清酸磷酸核糖基转移酶(EC 2.4.2.10)和乳清苷5'-单磷酸脱羧酶(EC 4.1.1.23)是尿苷5'-单磷酸(UMP)从头生物合成所需的六个酶促步骤中的最后两个。本实验室早期的研究表明,在小鼠艾氏腹水癌中,这两种酶活性都存在于单一的多功能多肽链——UMP合酶上。我们在此报告,胎盘是UMP合酶的一个可用人类来源,其乳清酸磷酸核糖基转移酶和乳清苷5'-单磷酸脱羧酶的比活性比红细胞高40倍,红细胞是其他人之前使用过的人类来源。通过将胎盘用作UMP合酶的来源,并开发一种与从艾氏腹水癌中纯化UMP合酶(哺乳动物UMP合酶的唯一其他均一制剂)所使用的方法不同的新型纯化程序,我们将人UMP合酶纯化至表观均一。这是关于从人类来源以及恶性细胞系以外的来源获得的UMP合酶均一性的首次报道。与早期报道相反,发现人胎盘UMP合酶是一种多功能蛋白,在分子量为51,000的单一多肽上包含两种酶活性。人胎盘UMP合酶的初步表征表明,它在亚基分子量、天然分子量、同工酶模式(尽管不是绝对的pI值)、酶活性的最适pH以及乳清苷5'-单磷酸(Km)和6-氮杂尿苷5'-单磷酸(Ki,在脱羧酶位点)动力学常数方面与艾氏腹水癌的UMP合酶相似。